Treatment of Breast Cancer Cells by IGF1R Tyrosine Kinase Inhibitor Combined with Conventional Systemic Drugs

Anticancer Research, 04/11/2012

Antagonistic effects should be anticipated when IGF1R inhibitors are combined with conventional systemic drugs in a subset of breast tumors. Development of functional biomarkers predicting tumor response to tailored insulin–like growth factor–1 receptor (IGF1R) therapy is warranted.

Print Article Summary Cat 2 CME Report